Guillermo Valenzuela, MD
Rheumatology · Plantation, FLNPI 1245252402
Payments from drug & device makers
Across 3,267 payments — averaging $4335.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4.2M
- Novartis$3.3M
- Janssen Research & Development, LLC$1.3M
- AbbVie$709K
- Eli Lilly$660K
- Gilead$623K
- plus $3.3M from 54 others
Across 16 payments — averaging $6371.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$85K
- Novartis$11K
- Amgen$3K
- Eli Lilly$2K
- Radius Health, Inc.$372
What the payments were for
- Consulting fees$308,91821%
- Speaking & faculty fees$994,16867%
- Travel & lodging$124,2028%
- Food & beverage$49,3003%
- Education$1,3050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,164,415 in reported general payments places this provider in the 95th percentile of 453 rheumatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BenlystaBelimumab | 149 | $642,495 |
| RemicadeInfliximab | 115 | $604,637 |
| OrenciaAbatacept/Maltose | 129 | $574,549 |
| ProliaDenosumab | 273 | $477,081 |
| Cimzia (2 Pack)Certolizumab Pegol | 63 | $410,121 |
| Simponi AriaGolimumab | 50 | $376,214 |
| ActemraTocilizumab | 142 | $374,960 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 15 | $357,396 |
| Humira(Cf) PenAdalimumab | 38 | $288,588 |
| InflectraInfliximab-Dyyb | 66 | $244,032 |
| RituxanRituximab | 16 | $233,343 |
| Enbrel SureclickEtanercept | 28 | $210,797 |
| RinvoqUpadacitinib | 28 | $181,040 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 14 | $161,950 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 22 | $160,383 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonRemicade, Simponi Aria | $60,674 | $980,851165 claims |
| AmgenProlia, Evenity (2 Syringes), Otezla | $4,197,919 | $755,400362 claims |
| GSKBenlysta | $226,779 | $642,495149 claims |
| Genentech, Inc.Actemra, Rituxan | $30 | $608,302158 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $220,188 | $574,549129 claims |
| UCB, Inc.Cimzia (2 Pack) | $119,310 | $410,12163 claims |
| Grifols USA, LLCGamunex-C | $23 | $357,39615 claims |
| PfizerInflectra | $116,295 | $244,03266 claims |
| AbbVieRinvoq | $708,667 | $181,04028 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $125,463 | $161,95014 claims |
| SanofiKevzara | $128,477 | $114,52127 claims |
| Radius Health, Inc.Tymlos | $42,312 | $90,26731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 453 rheumatology providers in Florida.
Other rheumatology in Plantation
- Martha Hernandez IllasFort Lauderdale$25M
- Carlos SesinMiami Beach$19M
- Marimer Rensoli VelazquezMiami$12.2M
- Robert LevinClearwater$11M
- Jigar ShahMargate$5.6M
- Michael BubbGainesville$3.3M
- Vipul JoshiBrandon$3.1M
- Alvin WellsDestin$2.9M
- Benidecto FernandezHialeah$2.9M
- Norman GaylisAventura$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.